Compare GTIM & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | COCP |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.3M |
| IPO Year | 1990 | N/A |
| Metric | GTIM | COCP |
|---|---|---|
| Price | $1.19 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 35.7K | ★ 92.6K |
| Earning Date | 02-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $141,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.90 |
| 52 Week High | $2.65 | $2.67 |
| Indicator | GTIM | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 37.45 |
| Support Level | $1.14 | $0.97 |
| Resistance Level | $1.26 | $1.06 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.67 | 4.50 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).